enGene Therapeutics Inc. 8K

enGene Therapeutics furnished a corporate presentation detailing interim clinical results and development plans for its lead NMIBC gene therapy detalimogene, including a planned BLA filing in 2H 2026 and strong cash resources to support advancement.

enGene Therapeutics Inc. furnished a July 2026 corporate presentation on its lead investigational non-viral gene therapy, detalimogene voraplasmid, for high-risk non-muscle-invasive bladder cancer (NMIBC), outlining interim Phase 2 LEGEND pivotal cohort data (54% any-time complete response rate with generally mild, reversible treatment-related adverse events), its development of a polidocanol surfactant bladder rinse to potentially enhance efficacy and durability, the anticipated timeline for a biologics license application (BLA) filing in the second half of 2026 with potential approval and platform designation in 2027, the breadth of ongoing LEGEND cohorts, and its financial position with approximately $285 million in cash expected to fund operations through planned BLA filing and potential approval.

Filing Facts

CIK

1980845

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-307795

Alert Tier

6